Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research report issued to clients and investors on Monday. They presently have a $67.00 target price on the stock. Jefferies Group LLC’s price objective would indicate a potential upside of 25.16% from the stock’s current price.
Several other research analysts have also recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 target price on shares of Neurocrine Biosciences in a research report on Friday, March 17th. Barclays PLC reaffirmed an “overweight” rating and issued a $60.00 target price on shares of Neurocrine Biosciences in a research report on Monday, March 27th. Piper Jaffray Companies reaffirmed an “outperform” rating and issued a $80.00 target price on shares of Neurocrine Biosciences in a research report on Tuesday, March 7th. Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research report on Friday, April 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $80.00 target price on shares of Neurocrine Biosciences in a research report on Tuesday, March 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $68.06.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 53.53 on Monday. The firm’s market capitalization is $4.71 billion. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $55.38. The firm’s 50 day moving average is $50.99 and its 200-day moving average is $45.65.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, May 9th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.23. During the same period in the previous year, the company earned ($0.22) earnings per share. On average, equities research analysts predict that Neurocrine Biosciences will post ($2.46) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Stock Rating Reaffirmed by Jefferies Group LLC” was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://sleekmoney.com/neurocrine-biosciences-inc-nbix-stock-rating-reaffirmed-by-jefferies-group-llc/1848891.html.
In other news, insider Malcolm Lloyd-Smith sold 9,960 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the completion of the sale, the insider now directly owns 17,997 shares in the company, valued at $965,179.11. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin Charles Gorman sold 19,596 shares of the firm’s stock in a transaction on Wednesday, April 12th. The shares were sold at an average price of $50.42, for a total value of $988,030.32. Following the completion of the sale, the chief executive officer now owns 332,913 shares of the company’s stock, valued at $16,785,473.46. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,360 shares of company stock valued at $4,967,989. Company insiders own 4.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Independent Portfolio Consultants Inc. acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $106,000. First Mercantile Trust Co. raised its stake in shares of Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after buying an additional 560 shares during the period. Opus Point Partners Management LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $206,000. Two Sigma Securities LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $212,000. Finally, Capstone Asset Management Co. acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $214,000. Institutional investors own 97.60% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/neurocrine-biosciences-inc-nbix-stock-rating-reaffirmed-by-jefferies-group-llc/1848891.html
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.